The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.

Innovators in the treatment of diuretic-resistant fluid overload liver disease - malignant ascites - heart failure Our company Helping patients live a more independent life Discover more for a better quality of life. DISCOVER MORE Proven ascites treatment Breakthrough approach to diuretic-resistant fluid overload Discover More

Sequana Medical, innovators in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure

We are a commercial stage medical device company utilizing our proprietary alfapump® and DSR (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective.

alfapump®, a fully implanted system for the automatic and continual removal of fluid

The alfapump® is a unique, fully implanted, wireless device that automatically pumps fluid from the abdominal cavity into the bladder, where it is naturally eliminated through urination.

In the U.S., the alfapump® has received Breakthrough Device status from the FDA and the pivotal POSEIDON study is ongoing. In Europe, the alfapump® has received CE mark and over 900 devices have been implanted to date.

Years cumulative pumping time
alfapump Implantations
Liters of ascites removed

DSR®, a proprietary approach to manage sodium and fluid overload

Direct Sodium Removal or DSR is managing sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity.
Clinical studies in diuretic-resistent heart failure patients demonstrated that DSR therapy is able to manage the fluid balance, restore diuretic response and improve cardio-renal function.

Patient stories, living with refractory ascites before and after the alfapump

Ascites has a dramatic impact on the quality of life of patients. Patients suffering from ascites are immobile and very restricted in their daily activities, and often report feelings of isolation and depression.

When we interviewed patients that had the alfapump® implanted, they all reported a substantial improvement in their daily life.

Clinical research, demonstrating the impact of our treatments

Through our ongoing development work and close collaboration with clinicians, we continue to grow the body of evidence for our alfapump® and DSR technologies, as shown by the multiple peer-reviewed journal publications.

Recent News

All news

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.